Click on headlines below to download research

Termination of coverage
Termination of coverage - SymBio Pharmaceuticals | 29/04/2022

Edison Investment Research is terminating coverage on Brooge Energy (BROG), Tyman (TYMN), SymBio Pharmaceuticals (4582), Aspire Global (0EAZ), CiiTECH…

...read more

The first whole quarter of internal SymBio sales
SymBio Pharmaceuticals | 27/05/2021

SymBio reported Q121 sales of ¥1.42bn of its drug Treakisym (bendamustine) for hematologic malignancies. This is the first quarter in which the product…

...read more

Treakisym approved for DLBCL
SymBio Pharmaceuticals | 30/03/2021

SymBio announced on 23 March 2021 that it has received marketing approval for Treakisym (bendamustine) for diffuse large B-cell lymphoma (DLBCL). The drug…

...read more